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Summary Forty patients with stage III and 15 patients with stage IVa carcinoma of cervix have been treated
with two pulses of cisplatin, vincristine and bleomycin combination chemotherapy before full dose radical
radiotherapy. Twenty-seven of 51 (53%, 95% confidence interval 40-67%) had an objective response to
chemotherapy and all chemotherapy responders had a complete response to radiotherapy. The actuarial
survival at 24 months of responders to chemotherapy is 71% against 37% for non-responders. The
responding patients had an estimated reduction in mortality to 36% (P=0.014, 95% CI 15-81%) of that of
the non-responders to chemotherapy. The incidence of tumour recurrence or distant metastases showed a
similar reduction to 34% (P=0.006, 95% CI 14-73%) of that of the non-responders. The data strongly
suggest that response to chemotherapy in the initial treatment of advanced cervical cancer is associated with
an improvement in survival following subsequent radical radiotherapy.
Both clinical studies (Shukovsky & Fletcher, 1973) and
animal experiments (Fowler et al., 1963) have shown that
radiation doses that will consistently eradicate small tumours
will only be effective in a minority of larger lesions. The
maximum radiation dose that can be given to patients with
advanced carcinoma of cervix is limited by the tolerance of
surrounding organs, such as the bladder and bowel.
Even employing what are currently regarded as optimal
fraction policies in combination with intracavity treatment,
local control is achieved in only about half of patients with
advanced carcinoma of cervix. Typical local recurrence-free
rates are 51% for stage III (Adams & Kerby, 1983) and 43%
for stage IVa patients (Upadhyay et al., 1988). The relative
radio-resistance of bulky tumours may in part be due to the
presence of hypoxic cells within the tumour as radiotherapy
in hyperbaric oxygen increased local control in one large
randomised series (Watson et al., 1978), but other factors
could also be important. Local control using conventional
radiotherapy schedules may be increased if the tumour size
could be reduced by chemotherapy given before radio-
therapy. Advanced carcinoma of cervix may be particularly
susceptible to this approach as the tumour is moderately
chemosensitive (Guthrie, 1985) and a proportion of lesions
which are locally far advanced may not have spread beyond
the true pelvis.
As a first step to testing this hypothesis we carried out a
pilot study of cisplatin-based chemotherapy given before full
dose radiotherapy.
Materials and methods
The first 55 patients who entered this pilot study have been
followed up for up to 51 months since the end of treatment
(median follow-up 21 months). Forty patients were assigned
to stage III and 15 to stage IVa; all had squamous
carcinomas. All the relevant biopsy material has been
retrospectively reviewed (without knowledge of which
patients responded to chemotherapy) using the grading
system of Reagan & Wentz (Gunderson et al., 1974). The
mean age of patients was 49 years (range 29-70) and all had
a WHO performance status of 2 or less and were fit for
radical chemotherapy and radiotherapy with a creatinine
clearance greater than 50mlmin-1.
On days 1 and 14 cisplatin 50mgm 2 was given by
infusion over 2h. This was followed by bleomycin 30mg,
hydrocortisone 150mg and vincristine 2mg (all given by
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slow injection). The cisplatin was preceded by 1 litre of
saline infused over 4h and followed by at least 3 litres of
fluid (mainly saline) over 24h to maintain urine output of
100mlh-1. Most patients also received high dose metoclo-
pramide (12mgkg-1) which was infused over 12h as an
anti-emetic. Radiotherapy began on day 28. A tumour dose
of 42.5Gy (4MeV X-rays) was given in 20 fractions over 28
days using a box technique (average volume 15 x 15 x 12cm).
A further 33.5Gy was given to the A points by intracavitary
caesium using 'Manchester' type sources at a dose rate of
0.55Gyh-1 or using a Selectron after-loading machine.
When the Selectron was used, the insertion dose was
reduced to compensate for the increased dose rate as
calculated by cumulative radiation effect formula (CRE)
(Kirk et al., 1972). Tumour size was estimated before
chemotherapy by examination under anaesthesia and pelvic
ultrasound. Response to chemotherapy was assessed using
standard UICC criteria by a further examination (without
anaesthesia) and ultrasound carried out before radiotherapy.
Response to radiotherapy was assessed 3 months after
finishing treatment by clinical examination and ultrasound if
indicated. Serial examinations were carried out by the same
clinician (T.H., R.P.S. or E.R.W.). Some patients had a
second examination by another clinician if there was any
doubt about the validity of tumour shrinkage. Actuarial
survival was calculated by the life table method and
statistical significance by the log rank test.
Results
Data from all 55 patients entered into the study were used to
evaluate survival and toxicity. Tumour response to chemo-
therapy was not assessed before radiotherapy in four cases,
leaving 51 eligible patients. Twenty-seven patients (53%) had
a partial response to chemotherapy (95% confidence limits
40-67%), 21 (41%) had stable disease and three (6%)
showed evidence of disease progression. Four patients had
only one pulse of chemotherapy (two were partial
responders): in two further chemotherapy was refused, one
patient had obvious tumour progression and the other
patient had a fall in creatinine clearance to 37mlmin-1.
The major toxic effect of chemotherapy was nausea and
vomiting (see Table I). Fifty patients received high dose
metoclopramide and the others varying prophylactic anti-
emetics. Renal damage sufficient to cause a rise in blood
urea or creatinine above the normal range was not seen. In
five cases the haemoglobin fell below 10gdl-1. We cannot
say if the anaemia was caused by the disease or chemo-
therapy. Only two patients developed leucopenia
(WBC<3.0 x 1091-1) and no white count fell below
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2.0 x 1091-1. Thrombocytopenia was not seen. Five patients
developed mild reversible alopecia.
All patients completed external beam radiotherapy as
planned and this was followed by intracavity caesium, except
for one patient where the intracavity treatment was delayed
by 5 weeks owing to diarrhoea and a coincidental throat
infection.
The use of chemotherapy before radiotherapy does not
appear to have increased the acute or late side effects of
radiotherapy. A minority suffered some nausea and vomiting
and the majority diarrhoea during radiotherapy (see Table
I).
A total of seven patients have developed high dose
radiation effects, five with bladder and two with rectal
symptoms. In four cases symptoms are mild. Two patients
developed marked haematuria and frequency. In both cases
the bladder was grossly involved by tumour but both
patients are tumour-free more than 3 years after treatment.
One patient required a colostomy.
All 27 patients who responded to chemotherapy had a
complete response to radiotherapy and the actuarial survival
of this group at 24 months is 71% (95% CI, 45-90%)
(Figure 1) with 69% (95% CI, 43-88%) being disease-free
(Figure 2). In comparison only 12 out of 24 (50%, 95% CI,
29-71%) of those who did not respond to chemotherapy had
a complete response to radiotherapy. The 24 months
actuarial survival of non-responders to chemotherapy is 37%
(95% CI, 14-65%) and only 35% (95% CI, 16-60%) are
tumour-free. Although the numbers in each group are small
the survival and disease-free survival differences between
each group are statistically significant, the P values being
Table I Acute toxicity of chemotherapy and radiotherapy
Chemotherapy-
WHO induced nausea Radiation-induced Radiation-induced
toxicity and vomiting nausea and vomiting diarrhoea
scale (No. ofpatients) (No. ofpatients) (No. ofpatients)
0 17 38 8
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0.018 and 0.005 respectively. There were no obvious
differences in distribution of factors likely to influence
prognosis between the two groups, such as patient's age,
tumour stage or tumour histology (Table II).
The actuarial survival at 48 months of all patients entered
into the study is 46%. The survival of stage IVa patients
(58%) is better than stage III patients (41%) but this
difference is not statistically significant (P=0.475) and is
almost certainly owing to chance and the small number in
this study.
Discussion
When planning this pilot study we were concerned in case
ineffective chemotherapy delayed radiotherapy which is of
proven value. Therefore only 1 month elapsed between the
start of chemotherapy and radiation treatment. We have
been able to demonstrate activity for this regimen of cis-
platin, bleomycin and vincristine and tumour progression
during chemotherapy was seen in only three cases. The
chemotherapy used was relatively non-myelosuppressive and
two pulses were given 14 days apart without delaying or
extending planned radiotherapy. The major side effect of
chemotherapy was nausea and vomiting and acute and late
effects of radiotherapy do not seem to have been increased.
The results of this study are in broad agreement with
those of Kirsten et al. (1987). An initial response to chemo-
therapy is associated with a high complete response rate to
radiotherapy and subsequent local control and good disease-
free survival. Two possible explanations exist to explain
these results. It is conceivable that radiotherapy is more
effective after the tumour has been debulked by chemo-
therapy or alternatively chemosensitive tumours are innately
more sensitive to radiotherapy. However, this apparent
radiosensitivity cannot be predicted in advance: it is
noteworthy that the histological appearances of responders
and non-responders are very similar.
Our results should be interpreted with some caution in
view of recent experiences in the treatment of squamous
carcinoma of head and neck, a group of tumours that has
some features in common with squamous carcinoma of
cervix. Both are moderately chemosensitive and local control
is very important. Of those head and neck tumours recurring
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Figure I Stage III and IVa carcinoma of cervix survival by response to chemotherapy.
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Figure 2 Stage III and IVa carcinoma of cervix disease-free survival by response to chemotherapy.
Table II Variables likely to alter prognosis of responders and non-
responders to chemotherapy
Responders Non-responders
(n =27) (n=24)
Mean age (years) 48 48
(range 31-69) (range 29-68)
No. of stage III cases 20 17
No. of stage IVa cases 7 7
Tumour differentiation
Grade I well differentiated 7 9
keratinising
Grade II large cell non- 19 15
keratinising
Grade III small cell 1 0
after apparently effective local treatment, 70% recur at the
original site and only 20-30% develop distant metastases
(Probert et al., 1974). Response to chemotherapy has been
shown to predict response to radiotherapy in this group of
patients (Ensley et al., 1984) but randomised trials have
failed to demonstrate any consistent survival advantage for
patients suffering from head and neck cancer treated by
radiotherapy and chemotherapy compared to radiotherapy
alone (Kun et al., 1986; Stell et al., 1983).
We do not know if the overall survival of patients in this
pilot study has been increased by the giving of chemotherapy
before radical radiotherapy. Nevertheless, our results are
encouraging and justify a randomised trial from which we
may be able to assess whether chemotherapy is merely a
predictor of response to radiotherapy or is indeed acting by
primary tumour reduction and thus leading to improved
local control and survival.
We are very grateful to Miss Alison Carnegie for typing the
manuscript and Mr Jim Paul for calculating the 95% confidence
limits.
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